We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/... Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. Show more
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncologyβs international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares...
Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has...
Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on track to submit rolling NDA for accelerated...
Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and their best response compared to most recent prior...
Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatments Ongoing Phase 3 RAMP 301 trial is evaluating avutometinib and defactinib in recurrent low-grade serous...
Β GFH375 (VS-7375), a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, demonstrated potent anti-tumor activity in pancreatic and colorectal cancer models; Partner GenFleet plans to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.48 | -13.5779816514 | 10.9 | 11.18 | 9.27 | 93940 | 9.94109019 | CS |
4 | -2.35 | -19.9660152931 | 11.77 | 12.26 | 9.27 | 99628 | 11.18018421 | CS |
12 | -2.13 | -18.4415584416 | 11.55 | 14.22 | 9.27 | 145860 | 11.92448864 | CS |
26 | 2.8 | 42.2960725076 | 6.62 | 14.22 | 5.94 | 113357 | 10.54365009 | CS |
52 | 4.56 | 93.8271604938 | 4.86 | 15.18 | 4.26 | 663110 | 11.0479589 | CS |
156 | -24.06 | -71.8637992832 | 33.48 | 59.22 | 3.474 | 1436976 | 22.37770682 | CS |
260 | -18.78 | -66.5957446809 | 28.2 | 59.22 | 3.474 | 2155867 | 22.33006602 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions